NCT04440527

Brief Summary

The aim of this project is to compare trabeculectomy with Preserflo / Innfocus Microshunt in patients with Primary Angle Open Glaucoma and Pseudoexfoliation Glaucoma regarding the reduction of intraocular pressure.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
70

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jul 2020

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 18, 2020

Completed
1 day until next milestone

First Posted

Study publicly available on registry

June 19, 2020

Completed
1 month until next milestone

Study Start

First participant enrolled

July 22, 2020

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 22, 2022

Completed
2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

July 22, 2024

Completed
Last Updated

June 19, 2020

Status Verified

June 1, 2020

Enrollment Period

2 years

First QC Date

June 18, 2020

Last Update Submit

June 18, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • Difference in intraocular pressure

    The primary endpoint is the difference between intraocular pressure after microshunt implantation vs trabeculectomy.

    1 year

Study Arms (2)

Microshunt

EXPERIMENTAL

Patients will be treated with Preserflo / Innfocus Microshunt (Santen Pharmaceutical Co., Ltd.).

Device: Preserflo / Innfocus Microshunt

Trabeculectomy

ACTIVE COMPARATOR

Patients will be treated with trabeculectomy.

Other: Trabeculectomy

Interventions

The Microshunt features an 8.5-mm tube with an outer diameter of 350 µm and a 70-µm diameter lumen. Implantation creates a subconjunctival bleb and lowers intraocular pressure by increasing aqueous humor outflow.

Microshunt

Trabeculectomy is the most commonly performed surgical procedure and is considered the gold standard.

Trabeculectomy

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age ≥ 18 years
  • Primary open angle glaucoma or pseudoexfoliation glaucoma
  • medically uncontrollable intraocular pressure or intolerance of topical therapy
  • negative urine/serum pregnancy test of women in childbearing age
  • signed and dated informed consent

You may not qualify if:

  • previous incisional glaucoma procedure on affected eye
  • pregnancy, nursing period
  • Patients in military service, training periods and civil service
  • Participation in another clinical trail
  • pre-existing ocular pathologies: high myopia (refraction ≥8.00 D), thin conjunctiva

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Medical University Innsbruck

Innsbruck, Tyrol, 6020, Austria

Location

MeSH Terms

Conditions

Glaucoma, Open-AngleExfoliation Syndrome

Interventions

Trabeculectomy

Condition Hierarchy (Ancestors)

GlaucomaOcular HypertensionEye DiseasesIris DiseasesUveal Diseases

Intervention Hierarchy (Ancestors)

Filtering SurgeryOphthalmologic Surgical ProceduresSurgical Procedures, Operative

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 18, 2020

First Posted

June 19, 2020

Study Start

July 22, 2020

Primary Completion

July 22, 2022

Study Completion

July 22, 2024

Last Updated

June 19, 2020

Record last verified: 2020-06

Locations